For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Fate Therapeutics Inc (NASDAQ: FATE) was $1.07 for the day, up 2.88% from the previous closing price of $1.04. In other words, the price has increased by $2.88 from its previous closing price. On the day, 1.69 million shares were traded. FATE stock price reached its highest trading level at $1.1 during the session, while it also had its lowest trading level at $1.0.
Ratios:
Our analysis of FATE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.04 and its Current Ratio is at 8.04. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.
On October 27, 2025, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 04 ’25 when TAHL CINDY sold 9,037 shares for $1.06 per share. The transaction valued at 9,573 led to the insider holds 397,670 shares of the business.
Valamehr Bahram sold 14,466 shares of FATE for $15,396 on Aug 04 ’25. The President and CEO now owns 334,898 shares after completing the transaction at $1.06 per share. On Aug 04 ’25, another insider, TAHL CINDY, who serves as the Officer of the company, bought 9,037 shares for $1.06 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 123402784 and an Enterprise Value of -18093224. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.57 while its Price-to-Book (P/B) ratio in mrq is 0.47. Its current Enterprise Value per Revenue stands at -2.136 whereas that against EBITDA is 0.112.
Stock Price History:
The Beta on a monthly basis for FATE is 2.37, which has changed by -0.58203125 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $3.50, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -12.41%, while the 200-Day Moving Average is calculated to be -8.12%.
Shares Statistics:
FATE traded an average of 2.18M shares per day over the past three months and 2601070 shares per day over the past ten days. A total of 114.66M shares are outstanding, with a floating share count of 109.59M. Insiders hold about 4.97% of the company’s shares, while institutions hold 70.84% stake in the company. Shares short for FATE as of 1760486400 were 7544331 with a Short Ratio of 3.46, compared to 1757894400 on 9877527. Therefore, it implies a Short% of Shares Outstanding of 7544331 and a Short% of Float of 7.46.
Earnings Estimates
. The current assessment of Fate Therapeutics Inc (FATE) involves the perspectives of 9.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.14 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.96 and -$1.37 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$1.17, with 9.0 analysts recommending between -$0.94 and -$1.46.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $3.54M, resulting in an average revenue estimate of $7.21M. In the same quarter a year ago, actual revenue was $13.63M
